Filtered By:
Source: Atherosclerosis
Condition: Diabetes
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Elevated remnant cholesterol in atherosclerotic cardiovascular disease in diabetes: A population-based prospective cohort study
Background and Aims: Elevated remnant cholesterol is causally associated with increased risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. We tested the hypothesis that elevated remnant cholesterol is associated with increased risk of peripheral artery disease, myocardial infarction, ischemic stroke, and any ASCVD in individuals with diabetes.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: B. Wadstr öm, K. Pedersen, A. Wulff, B. Nordestgaard Source Type: research
Type 2 diabetes mellitus, atherosclerosis, and ischemic stroke: Histopathological changes of the brain
Background and Aims: Type 2 diabetes mellitus is associated with a marked increase in the risk of atherosclerotic diseases, including cerebrovascular disease. Atherosclerosis and ischemic stroke in diabetic patients occur 4 times more often than in the general population. Our aim was to investigate the brain tissue of patients with type 2 diabetes mellitus who died from ischemic stroke.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: L. Volos, T. Mykhaylichenko Source Type: research
Triglyceride-lowering therapy for the prevention of cardiovascular events, stroke, and mortality in patients with diabetes: A meta-analysis of randomized controlled trials
Triglyceride (TG)-lowering therapy is efficient for the prevention of cardiovascular disease (CVD) in the general population; however, for diabetic individuals, it is more controversial. The purpose of this study was to pool the results from randomized controlled trials (RCTs) to clarify whether the lowering of TG is beneficial for the prevention of CVD events, stroke, and mortality in subjects with diabetes.
Source: Atherosclerosis - July 12, 2023 Category: Cardiology Authors: Xiu Hong Yang, Qian Ming Tu, Li Li, Yong Ping Guo, Nian Song Wang, Hui Min Jin Source Type: research
Allograft inflammatory factor-1, a multi-target regulator of atherosclerosis
Atherosclerosis is a chronic inflammatory disease of the arterial wall responsible for ischemic heart disease and stroke, the most frequent causes of death worldwide. Cardiovascular diseases are expected to remain the main cause of death globally within the next 15 years, owing to a rapidly increasing prevalence, mainly due to the rising incidence of obesity and diabetes on a global scale in both developed and developing economies. This forces us to consider new strategies for prediction, prevention, and treatment of cardiovascular disease [1].
Source: Atherosclerosis - August 22, 2019 Category: Cardiology Authors: Yujiao Zhang, Alain Tedgui, Hafid Ait-Oufella Source Type: research
Mir-206 Deficiency Results In A Favorable Phenotype: Relevance For Type-2 Diabetes Mellitus And Metabolic Syndrome
Background and Aims: Type-2 diabetes mellitus (T2DM) and metabolic syndrome (MS) are multifactorial and multigenic diseases and hallmarks for atherosclerosis and stroke. Characteristics of these diseases include glucose intolerance, insulin resistance, hypertension, and disorders in triglyceride and cholesterol metabolism. Despite intensive research in this area, major factors liable for T2DM and MS and in turn for treatment are still elusive.
Source: Atherosclerosis - August 4, 2019 Category: Cardiology Authors: G. Kostner, N. Vujic, D. Kratky Tags: Posters 26 - 29 May, 2019 Source Type: research
Cardiovascular Incomes In The Hypertensive And Diabetic Mediterranean Population Older Than 65 Years Old
Background and Aims: In Spain, hypertension and DM are major health problems. The importance of determining the CV risk associated with both is based on the evidence of simultaneous CV risk factors potentiate each other, giving rise to a total CV risk that is greater than the sum of its components. Our objective was to study the income from coronary heart disease, heart failure or stroke produced in these patients during follow-up.
Source: Atherosclerosis - August 4, 2019 Category: Cardiology Authors: B. Roig-Espert, J.J. Tamarit-Garc ía, A. González-Cruz-Cervellera, V. Pallarés-Carratalá, P. Morillas-Blasco Tags: Posters 26 - 29 May, 2019 Source Type: research
Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes: A Systematic Review And Meta-Analysis
Background and Aims: Glucagon-like peptide 1 receptor (GLP-1R) agonists, a novel class of antidiabetic agents, have been reported to exert neuroprotective effects in experimental stroke models, especially if treatment starts before stroke. We aimed to assess available data regarding the risk of stroke in diabetic individuals treated with GLP-1R agonists.
Source: Atherosclerosis - August 2, 2019 Category: Cardiology Authors: F. Barkas, M. Elisaf, S. Filippas-Ntekouan, E. Klouras, H. Milionis Tags: E-poster session Source Type: research
Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe
South Asian (SA) individuals represent a large, growing population in a number of European countries. These individuals, particularly first-generation SA immigrants, are at higher risk of developing type 2 diabetes, atherogenic dyslipidaemia, and coronary heart disease than most other racial/ethnic groups living in Europe. SAs also have an increased risk of stroke compared to European-born individuals. Despite a large body of conclusive evidence, SA-specific cardiovascular health promotion and preventive interventions are currently scarce in most European countries, as well as at the European Union level.
Source: Atherosclerosis - May 15, 2019 Category: Cardiology Authors: Miguel Cainzos-Achirica, Ugo Fedeli, Naveed Sattar, Charles Agyemang, Anne K. Jenum, John W. McEvoy, Jack D. Murphy, Carlos Brotons, Roberto Elosua, Usama Bilal, Alka M. Kanaya, Namratha R. Kandula, Pablo Martinez-Amezcua, Josep Comin-Colet, Xavier Pinto Tags: Review article Source Type: research
Incretin drugs as modulators of atherosclerosis
Atherosclerosis is a major underlying cause of ischemic heart diseases, ischemic stroke, and peripheral artery disease. Atherosclerotic plaque progression is characterized by chronic progressive inflammation of the arterial wall, endothelial cell dysfunction, and subendothelial lipoprotein retention. Incretin drugs, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase-IV (DPP-IV) inhibitors, are promising anti-hyperglycemic agents used for the treatment of type 2 diabetes mellitus (T2DM).
Source: Atherosclerosis - September 14, 2018 Category: Cardiology Authors: Enrique Gallego-Colon, Wojciech Wojakowski, Tomasz Francuz Tags: Review article Source Type: research
Glucagon-like peptide 1 receptor agonists and protection against stroke: a systematic review and meta-analysis
Aim: Glucagon-like peptide 1 receptor (GLP-1R) agonists, a novel class of antidiabetic agents, have been reported to exert neuroprotective effects in experimental stroke models, especially if treatment starts before stroke. We aimed to assess available data regarding the risk of stroke in diabetic individuals treated with GLP-1R agonists.
Source: Atherosclerosis - August 1, 2018 Category: Cardiology Authors: H. Milionis, F. Barkas, M. Elisaf Tags: Diabetes and Vascular Risk Source Type: research
Increased diabetes risk and interaction with social and medical events in patients upon stroke: Two nationwide studies
This study evaluated diabetes risk and post-diabetes adverse events in patients with stroke.
Source: Atherosclerosis - August 22, 2017 Category: Cardiology Authors: Lu-Min Chu, Chih-Chung Liu, Chun-Chieh Yeh, Yi-Cheng Chang, Chaur-Jong Hu, Chun-Chuan Shih, Yih-Giun Cherng, Ta-Liang Chen, Chien-Chang Liao Source Type: research
GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by hyperglycaemia and insulin resistance. Diabetes mellitus is well-established as a major risk factor for the development of cardiovascular disease (CVD). A collaborative meta-analysis of 102 prospective studies revealed that people with diabetes are exposed to two-fold excess risk for coronary heart disease and stroke after adjustment for lipid profiles and inflammatory markers [1]. Moreover, prevention of cardiovascular complications is regularly integrated in the regime of medical care in diabetic patients, as these patients have a similar ri...
Source: Atherosclerosis - August 18, 2017 Category: Cardiology Authors: Ya-Lan Ying, Yung-Chih Chen, Karin Jandeleit-Dahm, Karlheinz Peter Tags: Editorial Source Type: research
Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke
Aim: Hypercholesterolemia is one of the main risk factors of atherosclerosis development. Lipid disorders occur as a result of some genetic abnormalities or secondary to underlying disease, for example, diabetes mellitus. Insulin resistance in such patient is often the reason of hypertriglyceridemia and low serum high-density lipoprotein cholesterol concentrations. Hypertriglyceridemia is the most common lipid abnormality in young patients with myocardial infarction.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Olga Baturina, Olga Mironova Source Type: research
The effect of the presence and the level of dyslipidemia control on diabetic patients with first acute ischemic stroke
Aim: Study of the effect of the presence and the level of dyslipidemia control on patients with type 2 diabetes mellitus (T2DM) and a first acute ischemic stroke (AIS).
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Ioannis Kyriazis, Konstantinos Sgouros, Dimitra Stefani, Kalliopi Vallianou, Panagiotis Georgakopoulos, Ioannis Tsamis, Sophia Petropoulou, Ioannis Kachrimanidis, Kosntantina Kyre, Athanasios Drosos, Moyssis Lelekis Source Type: research
Glucagon-like peptide-1 agonists and protection against stroke: A systematic review and meta-analysis
Aim: Type 2 diabetes is associated with an increased risk of stroke and a worse outcome following stroke. Among glucose-lowering modalities only pioglitazone (a thiazolinedione) has been shown to protect against stroke. Nonetheless, evidence from experimental with novel antidiabetic agents, such as glucagon-like peptide-1 (GLP-1) agonists, suggests potential neuroprotective effects, especially if treatment starts before stroke. Thus, we aimed to meta-analyze available evidence regarding the risk of stroke in individuals receiving GLP-1 agonists.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Fotios Barkas, Moses Elisaf, Haralampos Milionis Source Type: research
